Promising malaria vaccine to be tested in first large field trial
The vaccine can confer up to 100% protection and will be tested in 2,100 people on the west African island of Bioko.
A malaria vaccine that can provide up to 100% protection against the disease will be tested in a large clinical trial for the first time, to study its efficacy under real-world conditions.
The trial will begin in early 2020 on Bioko, an island off the coast of Equatorial Guinea, and will involve 2,100 people aged 2–50 years. The trial is intended to provide the efficacy and safety data needed for regulatory approval, says malaria researcher Steve Hoffman, who is leading the study and is chief executive of Sanaria, the company in Rockville, Maryland, that developed the vaccine. Equatorial Guinea’s government and private energy companies are sponsoring the trial.
In laboratory studies, the vaccine, called PfSPZ, has proven the most effective malaria vaccine developed so far, giving healthy volunteers complete protection.
By: Declan Butler/Nature News